Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$9.26
0.434.87%
At close: -
$9.20
-0.06-0.65%
After Hours: 7:45 PM EDT
Comments
Loading...
Zevra Therapeutics Analyst Ratings and Price Targets | NASDAQ:ZVRA | Benzinga
Zevra Therapeutics Inc has a consensus price target of $21.44 based on the ratings of 11 analysts. The high is $25 issued by Cantor Fitzgerald on May 14, 2025. The low is $17 issued by JMP Securities on September 24, 2024. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Canaccord Genuity, and Guggenheim on May 14, 2025, March 13, 2025, and March 13, 2025, respectively. With an average price target of $24 between Cantor Fitzgerald, Canaccord Genuity, and Guggenheim, there's an implied 160.87% upside for Zevra Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Canaccord Genuity
Guggenheim
HC Wainwright & Co.
Citizens Capital Markets
1calculated from analyst ratings
Analyst Ratings for Zevra Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2025 | Buy Now | 171.74% | Cantor Fitzgerald | Kristen Kluska71% | $25 → $25 | Reiterates | Overweight → Overweight | Get Alert |
| 03/13/2025 | Buy Now | 171.74% | Canaccord Genuity | Sumant Kulkarni44% | $23 → $25 | Maintains | Buy | Get Alert |
| 03/13/2025 | Buy Now | 139.13% | Guggenheim | Eddie Hickman54% | $20 → $22 | Maintains | Buy | Get Alert |
| 03/13/2025 | Buy Now | 117.39% | HC Wainwright & Co. | Oren Livnat62% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | 95.65% | Citizens Capital Markets | Jason Butler52% | $17 → $18 | Maintains | Market Outperform | Get Alert |
| 03/12/2025 | Buy Now | 171.74% | Cantor Fitzgerald | Kristen Kluska71% | $25 → $25 | Reiterates | Overweight → Overweight | Get Alert |
| 11/20/2024 | Buy Now | 117.39% | HC Wainwright & Co. | Oren Livnat62% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 150% | Canaccord Genuity | Sumant Kulkarni44% | $25 → $23 | Maintains | Buy | Get Alert |
| 10/11/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
| 10/07/2024 | Buy Now | 117.39% | Guggenheim | — | → $20 | Initiates | → Buy | Get Alert |
| 10/01/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
| 09/30/2024 | Buy Now | 117.39% | HC Wainwright & Co. | Oren Livnat62% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 09/24/2024 | Buy Now | 84.78% | JMP Securities | Jason Butler52% | → $17 | Initiates | → Market Outperform | Get Alert |
| 09/24/2024 | Buy Now | 171.74% | Maxim Group | Jason McCarthy41% | $18 → $25 | Maintains | Buy | Get Alert |
| 09/24/2024 | Buy Now | 128.26% | Roth MKM | Jonathan Aschoff34% | $19 → $21 | Maintains | Buy | Get Alert |
| 09/20/2024 | Buy Now | 117.39% | HC Wainwright & Co. | Oren Livnat62% | $18 → $20 | Maintains | Buy | Get Alert |
| 09/18/2024 | Buy Now | 139.13% | Canaccord Genuity | Sumant Kulkarni44% | $24 → $22 | Maintains | Buy | Get Alert |
| 08/14/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
| 08/05/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
| 08/05/2024 | Buy Now | 95.65% | HC Wainwright & Co. | Oren Livnat62% | $15 → $18 | Maintains | Buy | Get Alert |
| 07/09/2024 | Buy Now | 63.04% | HC Wainwright & Co. | Oren Livnat62% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | Buy Now | 63.04% | HC Wainwright & Co. | Oren Livnat62% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 04/01/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | — | Reiterates | → Overweight | Get Alert |
| 03/12/2024 | Buy Now | — | William Blair | Tim Lugo31% | — | Initiates | → Outperform | Get Alert |
| 03/05/2024 | Buy Now | 63.04% | HC Wainwright & Co. | Oren Livnat62% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 12/28/2023 | Buy Now | 63.04% | HC Wainwright & Co. | Oren Livnat62% | $10 → $15 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 160.87% | Canaccord Genuity | Sumant Kulkarni44% | $20 → $24 | Maintains | Buy | Get Alert |
| 10/06/2023 | Buy Now | 171.74% | Roth MKM | Jonathan Aschoff34% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 09/01/2023 | Buy Now | 117.39% | Canaccord Genuity | Sumant Kulkarni44% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | Buy Now | 117.39% | Canaccord Genuity | Sumant Kulkarni44% | $19 → $20 | Maintains | Buy | Get Alert |
| 03/17/2023 | Buy Now | 30.43% | Maxim Group | Jason McCarthy41% | → $12 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Zevra Therapeutics (ZVRA) stock?
The latest price target for Zevra Therapeutics (NASDAQ:ZVRA) was reported by Cantor Fitzgerald on May 14, 2025. The analyst firm set a price target for $25.00 expecting ZVRA to rise to within 12 months (a possible 171.74% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Zevra Therapeutics (ZVRA)?
The latest analyst rating for Zevra Therapeutics (NASDAQ:ZVRA) was provided by Cantor Fitzgerald, and Zevra Therapeutics reiterated their overweight rating.
When was the last upgrade for Zevra Therapeutics (ZVRA)?
There is no last upgrade for Zevra Therapeutics
When was the last downgrade for Zevra Therapeutics (ZVRA)?
There is no last downgrade for Zevra Therapeutics.
When is the next analyst rating going to be posted or updated for Zevra Therapeutics (ZVRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zevra Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zevra Therapeutics was filed on May 14, 2025 so you should expect the next rating to be made available sometime around May 14, 2026.
Is the Analyst Rating Zevra Therapeutics (ZVRA) correct?
While ratings are subjective and will change, the latest Zevra Therapeutics (ZVRA) rating was a reiterated with a price target of $25.00 to $25.00. The current price Zevra Therapeutics (ZVRA) is trading at is $9.20, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
